Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

From finger-stick blood glucose monitoring and mechanical insulin pens in the 1970s to modern automated insulin delivery systems, rapidly progressing advances in diabetes technology are transforming management options for people with diabetes, particularly those with type 1 diabetes but also, increasingly, people with type 2 diabetes. However, access to life-changing diabetes technologies is neither uniform nor universally covered, and there is no one-size-fits-all approach. In this position statement, we emphasize to health care professionals the importance of supporting individuals with diabetes to access and use the right diabetes technology according to personal needs, capabilities, and preferences. In doing so, we highlight the equal importance of avoiding disparities in the provision of diabetes technology by challenging preconceived barriers, which can be overcome with education and determination. We also make a series of suggestions for action to advance the more widespread adoption of diabetes technology while minimizing the "digital divide."

Authors

Institutions

Publication Details

Journal
Diabetes Care
Published
2026-03-12
DOI
https://doi.org/10.2337/dci26-0018
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

M. ELEANOR EVANS, JR Petrie, Daniela Bruttomesso, A. C. B. Peters et al.
Diabetes Care
Diabetes Management and Research
article

Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

M. ELEANOR EVANS, JR Petrie, Daniela Bruttomesso, A. C. B. Peters, Jennifer L. Sherr, Helene Hanaire, Reinhard W. Holl, G. Alexander Fleming, Lutz Heinemann, Richard M. Bergenstal
article en

Abstract

From finger-stick blood glucose monitoring and mechanical insulin pens in the 1970s to modern automated insulin delivery systems, rapidly progressing advances in diabetes technology are transforming management options for people with diabetes, particularly those with type 1 diabetes but also, increasingly, people with type 2 diabetes. However, access to life-changing diabetes technologies is neither uniform nor universally covered, and there is no one-size-fits-all approach. In this position statement, we emphasize to health care professionals the importance of supporting individuals with diabetes to access and use the right diabetes technology according to personal needs, capabilities, and preferences. In doing so, we highlight the equal importance of avoiding disparities in the provision of diabetes technology by challenging preconceived barriers, which can be overcome with education and determination. We also make a series of suggestions for action to advance the more widespread adoption of diabetes technology while minimizing the "digital divide."

Diabetes Care
University of Southern California (US), University of Padua (IT), Zimmer Biomet (Netherlands) (NL), Université Fédérale de Toulouse Midi-Pyrénées (FR), Harper College (US), University of Cambridge (GB), Yale University (US), Toulouse Mathematics Institute (FR), Wellcome/MRC Institute of Metabolic Science (GB), Marien Hospital Düsseldorf (DE), Deutsches Diabetes-Zentrum e.V. (DE), German Center for Diabetes Research (DE), Heinrich Heine University Düsseldorf (DE), HealthPartners (US), University of Glasgow (GB)
Park Nicollet Foundation, Eli Lilly and Company, AstraZeneca, Sanofi, Insulet Corporation, MannKind Corporation, Dexcom, Novo Nordisk, European Association for the Study of Diabetes, Roche Diabetes Care, U.S. Food and Drug Administration, Abbott Diabetes Care, Moonshot Research and Development Program
Quality Education
Openalex Percentile: Top 27%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.